Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
With a market cap of 147.45B, Pfizer(PFE) trades at $25.80. The stock has a price-to-earnings ratio of 15.54 and currently yields dividends of 6.5%.
During the trading session on 2026-02-03, Pfizer(PFE) shares reached a daily high of $26.54 and a low of $25.14. At a current price of $25.80, the stock is +2.6% higher than the low and still -2.8% under the high.
Trading volume for Pfizer(PFE) stock has reached 91.7M, versus its average volume of 50.81M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 0.19% to 49,316.23 while the NA...
Image source: The Motley Fool. Feb. 3, 2026 at 10:00 a.m. ET Call participants Chairman and Chief Executive Officer — Albert Bourla Chief Scientific Officer —...
Is Pfizer stock a buy at under 9x earnings? Yes. It is. Pfizer (PFE 3.00%) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat...
Analyst ratings
57%
of 28 ratingsMore PFE News
On Tuesday, Pfizer Inc. (NYSE:PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus es...
Technology Pfizer Dives After Reaffirming Its Modest Outlook And Providing An Obesity Update Licensing Pfizer (PFE) stock toppled early Tuesday after the S&P 50...
Pfizer highlighted the performance of a weight-loss drug it acquired in last year's deal to buy Metsera. Pfizer on Tuesday hailed a study of a weight-loss drug...
Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline. Maxim Shemetov/Reuters Pfizer PFE 0.83 %...
Pfizer beats Q4 estimates, releases mid-stage GLP-1 trial results, and maintains guidance for full-year 2026 Pfizer slipped in early trading, down 1% as of 7:0...
Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial....
Reports Q4 revenue $17.56B, consensus $16.83B. David Denton, CFO and EVP of Pfizer (PFE): “I’m pleased with our solid financial results in 2025. With focused co...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.